Phenytoin dosage in the elderly. 1977

D C Lambie, and F I Caird

Measurement of serum-phenytoin concentrations in 17 elderly patients showed that levels of 40 mumol/l or more were not produced by daily doses of less than 300 mg/day, but that doses of 350 mg/day or more produced higher and potentially toxic levels. Determination of mean values for Vmax and Km for phenytoin gave values little different from those for younger patients. The implications of these findings for anticonvulsant therapy in the elderly are discussed.

UI MeSH Term Description Entries
D008297 Male Males
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

D C Lambie, and F I Caird
February 1990, Journal of clinical pharmacy and therapeutics,
D C Lambie, and F I Caird
November 1998, Pediatrics,
D C Lambie, and F I Caird
May 1978, Neurology,
D C Lambie, and F I Caird
August 1973, Lancet (London, England),
D C Lambie, and F I Caird
August 1973, Lancet (London, England),
D C Lambie, and F I Caird
August 1975, Lancet (London, England),
D C Lambie, and F I Caird
August 1994, Chemical & pharmaceutical bulletin,
D C Lambie, and F I Caird
July 1981, The Journal of pediatrics,
D C Lambie, and F I Caird
April 1981, Journal of pharmacokinetics and biopharmaceutics,
D C Lambie, and F I Caird
March 1981, Drug intelligence & clinical pharmacy,
Copied contents to your clipboard!